Location: 6001 Executive Blvd, Rockville, MD 20852 / Zoom
Despite substantial public and private interest in developing therapeutics for the Parkinson’s disease (PD) community, there persists separation between disease understanding and development of drugs to target these processes in Parkinson’s patients. The NINDS is convening a hybrid workshop with the overarching goal to (1) delineate what the crucial elements of those gaps are and (2) determine how to close those gaps as a community of stakeholders, including academic researchers, industry partners, non-profit organizations, and people with lived experience of Parkinson’s Disease.
This workshop is co-chaired by Alice Chen-Plotkin, MD, Parker Family Professor of Neurology, University of Pennsylvania School of Medicine and William Martin, PhD, Global Therapeutic Area Head, Neuroscience at Johnson & Johnson Innovative Medicine.
For further information, please contact Neel Dhruv neel.dhruv@nih.gov
Agenda
View a list of resources and articles for attendees(pdf, 254 KB) from our speakers in support of this workshop.
Day 1 - April 23, 2024 (All times listed are Eastern)
Time | Presentation |
---|---|
9:00 AM |
NINDS Welcome |
9:10 AM |
Engaging the Lived Experience Perspective on PD Therapeutics |
9:20 AM |
Workshop Co-Chairs Welcome and Goals for the 2 Days |
10:00 AM |
Break (5 minutes) |
Time | Presentation |
---|---|
10:05 AM |
Motor Heterogeneity in Parkinson’s Disease: Challenges to Therapeutic Developments |
10:20 AM |
Heterogeneity of Non-Motor Symptoms across Lewy Body Diseases |
10:35 AM |
Q & A Discussion (30 minutes) |
11:05 AM |
Break (10 minutes) |
Time | Presentation |
---|---|
11:15 AM |
Evolving Arcs toward Disease-Modifying Therapy for Parkinson’s |
11:30 AM |
Targeting LRRK2: Why, Who, Where and When |
11:45 AM |
An Industry Perspective on Target Validation For Neurologic Diseases |
12:00 PM | Q & A Discussion (30 minutes) |
12:30 PM |
Lunch (60 minutes) |
Time | Presentation |
---|---|
1:30 PM |
Teeing Up a Discussion about Appropriate Tools to Enable Therapeutics Development |
1:45 PM |
Preclinical Tools to Advance Parkinson Disease Therapeutics: What They Can and Cannot Do |
2:00 PM |
Q & A Discussion (30 minutes) |
2:30 PM |
Break (10 minutes) |
Time | Presentation |
---|---|
2:40 PM |
AI-Enabled Biomarkers: A Window into Parkinson’s Progression, Detection, and Treatment Response |
2:55 PM |
Identification of Proteomic Targets and Biomarkers: The Mapping Proteomics to Parkinson’s Disease Project (MAP2PD) |
3:10 PM | Understanding Biomarker Parameters to Enable Clinical Trials in Parkinson’s Disease Danielle Graham, PhD Head of Fluid Biomarkers and Bioanalysis, Biogen |
3:25 PM |
Q & A Discussion (30 minutes) |
3:55 PM |
Break (15 minutes) |
Time | Presentation |
---|---|
4:10 PM |
Parallel Breakout Session |
4:55 PM |
Break (5 minutes) |
5:00 PM | Day 1 Wrap-up |
5:10 PM |
Adjourn for the day |
Day 2 - April 24, 2024 (All times listed are Eastern)
Time | Presentation |
---|---|
8:45 AM |
Workshop Co-Chairs Welcome |
8:55 AM |
Reports from Breakout Sessions and Q & A |
10:00 AM |
Break (10 minutes) |
Time | Presentation |
---|---|
10:10 AM |
Disease-Modifying Therapies: Lessons from Alzheimer’s Disease Drug Development |
10:25 AM |
RNA-Target Therapies for Neurodegenerative Disease |
10:40 AM |
Q & A Discussion (30 minutes) |
11:10 AM |
Break (10 minutes) |
Time | Presentation |
---|---|
11:20 AM |
Addressing the Academia-Industry Gap to Advance Discoveries to the Clinic |
11:35 AM |
LRRK2 Inhibitors: From Basic Biology to the Clinic |
11:50 AM |
Opportunities and Challenges in Parkinson’s Disease Clinical Development using the Example of the SCD Inhibitor YTX-7739 |
12:05 PM | Q & A Discussion (30 minutes) |
Time | Presentation |
---|---|
12:35 PM |
Day 2 Wrap-up |
12:45 PM |
Adjourn / Lunch (75 minutes) |
Time | Presentation |
---|---|
2:00 PM |
Parallel breakout sessions
|
3:00 PM |
Adjourn |
Speaker Bios
Post Event Summary
Roundtable Executive Summaries
- Industry Roundtable(pdf, 146 KB)
- Nonprofit Roundtable(pdf, 146 KB)
- Academia Roundtable(pdf, 193 KB)